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In patients with human immunodeficiency virus (HIV) infection, lamivudine is used as a first-line drug for antiretroviral therapy. Lamivudine
is relatively nontoxic in nature, and it can also be used during pregnancy. Herein, we describe a 43-year-old, HIV-positive female hospitalized
with maculopapular, pruritic rash that appeared first on the extremities and gradually spread with systemic symptoms such as fever and
myalgia after lamivudine therapy.Keywords: Antiretroviral therapy, lamivudine, skin rashAddress for correspondence: Mr. Kashif Ullah Khan, Department of Clinical
Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia,
Penang 11800, Malaysia.INTRODUCTION
In patients with human immunodeficiency virus (HIV)
infection, lamivudine is used as a first-line drug for
antiretroviral (ARV) therapy. Lamivudine is a member of
the nucleoside reverse transcriptase inhibitors (NRTIs) group
of therapy. In combination with other NRTIs such as
zidovudine, lamivudine acts synergistically and strengthens
the antiviral effects.[1] Lamivudine is found to be relatively
nontoxic in nature and can be used during pregnancy.
Lamivudine may be included as part of postexposure
prevention in thosewho have been potentially exposed to HIV.
For the past few decades, there has been a massive increase in
the number of HIV-infected patients. The use of ARV drugs
plays a significant role in improving the quality of life of the
HIV-infected patients as well as disease-related morbidity of
these patients. However, along with the benefits of ARV
drugs, there are also a number of adverse reactions including
skin rashes. Among non-nucleoside reverse transcriptase
inhibitors (NNRTIs), nevirapine usage is the most common
reason for dermatological reactions, though lamivudine
(NRTI) is also rarely considered responsible for causing
skin rashes in HIV-infected patients, which sometimes
may lead to discontinuation of the therapy.[2] We report a
case of skin rashes developed in a patient after the





© 2017 ArchiveCASE REPORT
A 43-year-old, HIV-positive female with a CD4 count of 189
cells/mL was initiated with zidovudine, lamivudine, and
nevirapine for highly active antiretroviral therapy (HAART).
The patient was hospitalized with maculopapular, pruritic rash
that appeared first on the extremities and gradually dispersed
with systemic symptoms such as fever and myalgia, which
started from the 12th day after initiation ofHAART.Thepatient
was already on co-trimoxazole prophylaxis for more than 3
weeks and was tolerating it well. Routine laboratory
investigations including liver and kidney functions and
hemogram were normal. However, physical examination of
the patient showed an increase in body temperature and rash on
the trunkand the extremitieswithout anymucosal involvement.
After HAART and all other medications including co-
trimoxazole were stopped, the patient improved within a few
hours, and the rash completely disappeared by the 14th day.
After the disappearance of rash completely in 3 weeks, a
decision was taken to introduce a combination of
zidovudine, lamivudine, and efavirenz. Nevirapine wasE-mail: kashif00khan@gmail.com
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rash reappeared with more severity and extensive
distribution after the third dose of HAART. The rash
disappeared after stopping all of the ARVs. Thereafter,
a decision to initiate treatment with lopinavir/ritonavir
along with zidovudine and lamivudine and completely
exclude any NNRTI was taken. The initiation of the
new regimen did not improve the rash condition, and
the regimen was forced to stop.
After withdrawal of all ARV drugs, the rash disappeared
within 10 days. In the next regimen, lamivudine was
substituted with didanosine, because zidovudine and
lamivudine were the common denominator in all the
three ARV regimens. After zidovudine, didanosine, and
lopinavir/ritonavir were initiated, the patient did not
develop any rash further. Efavirenz was substituted instead
of lopinavir/ritonavir after 2 months.
DISCUSSION
There is an increased risk of developing mucocutaneous drug
reaction in an HIV-infected patient.[3] When any cutaneous
reaction appears simultaneously with the initiation of
zidovudine/stavudine, lamivudine, and nevirapine/efavirenz
treatment in an HIV-infected patient, normally the NNRTI
component is most commonly considered as the causative
agent. NNRTIs such as nevirapine and efavirenz are often
given under close medical supervision to the HIV-infected
patients with mild-to-moderate rash.[2] In severe cases such
asStevens–Johnsonsyndrome,NNRTIs arenever reintroduced
to the patient, and alternative agents such as ritonavir-boosted
atazanavir or lopinavir (PIs) are started. After NNRTI, the
commonly suspected group as the offending agent of cutaneous
reaction is NRTI. Zidovudine and lamivudine have been
reported to be associated with skin rash very rarely. The first
case of lamivudine-associated skin rashes was reported in
a 49-year-old male, in whom it appeared anaphylactically
after the first dose of lamivudine (150mg).[4] During the
HAART containing lamivudine, almost 80% of the patients
experienced an adverse drug reaction either from altered drug
metabolism, polypharmacy, or immune dysregulation.[5]
Dermatitis was reported in healthcare workers taking
lamivudine for postexposure prophylaxis.[6] Another case
was in a patient with chronic hepatitis B, in whom it was
reported that lamivudine caused an incidence of severe skin
eruptionand led todiscontinuationof thedrug.[7] It isdifficult to
manage patients with lamivudine intolerance without
availability of single-drug formulation, because lamivudineArchives of Pharmacy Practice ¦ Volume 8 ¦ Issue 2 ¦ April-June 2017is available only as fixed-dose coformulation with other
NRTIs such as zidovudine, stavudine, and tenofovir.
Lamivudine-associated adverse drug reactions sometimes
may lead to discontinuation of the therapy; therefore,
clinicians must be aware of such adverse reactions, even
though it has been an effective, widely used, and safe ARV
drug.
CONCLUSION
The skin rash seen in this reported patient was observed on
starting HAART and was triggered after re-exposure to
lamivudine within 1–2 days. The temporal relation
between appearance of rash and lamivudine initiation,
rapid regression after its discontinuation, relapse following
its reintroduction, and tolerance to lamivudine-sparing
regimens confirmed the causal relationship. Clinicians
must be aware of such severe, adverse reactions to
lamivudine, which may require treatment discontinuation,
so that swift treatment can be given to such patients.
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